CHICAGO—Atorvastatin (Lipitor) is as effective in preventing major cardiovascular events in type 2 diabetics who have impaired renal function as it is in those with normal renal function, according to data presented here at the 67th Scientific Sessions of the American Diabetes Association.
Combining an ACE inhibitor (ACEI) and angiotensin-receptor blocker (ARB) with enzyme replacement therapy using agalsidase-beta (Fabrazyme, Genzyme) may help stop progressive loss of kidney function in patients with severe kidney involvement due to Fabry disease, researchers report.
Decreasing levels of vitamin D are associated with increases in the prevalence in albuminuria, according to an epidemiologic study.
High ambulatory but normal or well-controlled office BP, a condition known as “reverse white-coat hypertension,” is an independent risk factor for microalbuminuria in patients with treated hypertension.
High-protein diets have been shown to accelerate renal deterioration in a number of studies of populations with even mildly reduced kidney function.
High cumulative exposure to nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with an increased risk for rapid CKD progression in the elderly, new data suggest.
Early folate supplementation by lowering plasma total homocysteine (tHcy) may prevent cardiovascular deterioration in patients with chronic renal failure, according to researchers in Brazil.
Starting anemia non-dialysis CKD patients on extended-dosing regimens of epoetin alfa can safely and effectively achieve target hemoglobin levels, data show.
Two studies suggest once-monthly dosing of darbepoetin alfa (Aranesp, Amgen) can effectively treat CKD anemia.
Adequate protein intake may improve albumin levels in hemodialysis patients, study says.
